India's drug regulations have been updated to include advanced treatments like cell, stem cell, gene therapies, and xenografts under central licensing. This move aims to bolster oversight for these complex, evolving medical technologies, ensuring patient safety and uniform standards nationwide. The amendment signifies a commitment to public health while fostering innovation and faster adoption of cutting-edge healthcare solutions.